NCT04612972View on ClinicalTrials.gov

Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru

PHASE3CompletedINTERVENTIONAL
Enrollment

12,000

Participants

Timeline

Start Date

September 9, 2020

Primary Completion Date

February 19, 2021

Study Completion Date

April 3, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo

This clinical trial is conducted in randomized, blind, placebo controlled design Total sample size is 12 000, which are randomly allocated into investigational vaccine 1, investigational vaccine 2 and placebo control group.

Trial Locations (1)

L-031

Av. Honorio Delgado 430, Urb. Ingeniería, San Martín de Porres

All Listed Sponsors
collaborator

National University of San Marcos, Peru

OTHER

lead

Universidad Peruana Cayetano Heredia

OTHER

NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru | Biotech Hunter | Biotech Hunter